## Why BP vs. MDD?

Knowing the genomic differences between **Major Depressive Disorder** (MDD) and **Bipolar Disorder** (BP) is critically important, primarily to improve diagnosis, guide treatment selection, and enhance our fundamental understanding of these distinct conditions.

The genomic differences are crucial for several reasons:
* Accurate and Early Differential Diagnosis [[1 ,2 ](#references)]  
* Personalized and Effective Treatment [[3 ,4](#references)]
* Understanding Disease Biology [[5](#references)]

## Why Amygdala and sgACC?
The **amygdala** and the **subgenual anterior cingulate cortex (sgACC)** are two of the most consistently implicated brain regions in the neurobiology of mood disorders like Major Depressive Disorder (MDD) and Bipolar Disorder (BP). They are critical components of the brain's **limbic system**, which is essential for emotional processing and regulation.

## Amygdala: The Emotional Sentinel
The amygdala is primarily known as the brain's "fear center," but its function is broader, acting as a critical hub for the **salience** (emotional significance) of stimuli, especially negative ones, and for the formation of **emotional memories**.

### Role in MDD
* **Hyperactivity to Negative Stimuli:** In MDD, the amygdala often shows **hyperactivity** or heightened reactivity, especially when processing negative emotional stimuli (e.g., sad or fearful faces). This is consistent with the negative emotional bias and exaggerated stress response characteristic of depression.
* **Impaired Regulation:** This hyperactivity is often attributed to a failure of **top-down regulation** from the prefrontal cortex (PFC), which normally dampens the amygdala's response. The amygdala's constant alarm state contributes to symptoms like anxiety, rumination, and chronic stress.
* **Structural Changes:** Some studies indicate an increase in amygdala volume in medication-na√Øve MDD patients.

### Role in Bipolar Disorder (BP)
The amygdala's role in BP is often described as **state-dependent**, meaning its activity changes with the mood episode:
* **Mania:** The amygdala shows **hyperactivity** and increased volume during manic episodes, which aligns with symptoms like increased arousal, heightened emotionality (euphoria or irritability), and impulsivity.
* **Depression:** During the depressive phase of BP, the amygdala's activity is sometimes reported to be **reduced** (hypoactivity) compared to manic states or even healthy controls, though findings can be mixed.
* **Trait Vulnerability:** Persistent deficits in the ability of the PFC to regulate the amygdala are considered a core vulnerability for BP across all mood states.

## üéØ Subgenual Anterior Cingulate Cortex (sgACC): The Mood Regulator
The sgACC (often referred to as Brodmann Area 25) is a small but highly influential region deep within the front of the brain. It is considered a **key node** in the network that connects emotional limbic areas (like the amygdala) with cognitive prefrontal regions. It plays a central role in modulating emotional, visceral, and neuroendocrine responses (like the stress hormone cortisol).

### Role in MDD and BP (Shared Features)
The sgACC shows a unique and critical pattern of dysfunction in both MDD and BP depression:

* **Structural Abnormality:** Both MDD and BP patients show a consistent finding of an **abnormally reduced gray matter volume** in the sgACC compared to healthy individuals. This reduction is often attributed to a loss of **glial cells** (support cells in the brain), not neurons, and may be present irrespective of the current mood state.
* **Metabolic Hyperactivity in Depression:** During depressive episodes (in both MDD and BP), the sgACC typically displays **elevated metabolic activity** (hyperactivity). This "hot spot" is hypothesized to drive or maintain the depressive state.
* **Treatment Target:** The sgACC is a significant target for effective treatments:
    * Successful antidepressant treatment is often associated with a **reduction (normalization)** of this sgACC hyperactivity.
    * **Deep Brain Stimulation (DBS)** targeting the sgACC has shown remarkable success in treating otherwise treatment-resistant depression, by essentially quieting the overactive circuit.

### Distinct Functional Connectivity
While both regions are involved in both disorders, the specific ways they connect and interact with other brain areas may differ, offering clues for differential diagnosis:

| Feature | Major Depressive Disorder (MDD) | Bipolar Disorder (BP) |
| :--- | :--- | :--- |
| **Amygdala Activity** | Consistently **Hyperactive** (especially to negative stimuli). | **State-Dependent** (Hyperactive in mania, variable/sometimes hypoactive in depression). |
| **sgACC Structure** | **Reduced Volume** (A trait-like abnormality). | **Reduced Volume** (A trait-like abnormality, similar to MDD). |
| **sgACC Activity** | **Hyperactive** during the depressive state. | **Hyperactive** during the depressive state. |
| **Connectivity** | Disrupted connectivity between the amygdala and frontal regulatory areas. Often **increased sgACC-amygdala connectivity** in depressed adolescents. | May show distinct patterns of **prefrontal-amygdala** and **sgACC-amygdala** connectivity, particularly during mania, where the regulatory failure is pronounced. |

## Motivation of analyzing **Gene, Exon, Junction, and Transcript (Isoform)**

Focusing on different resolution levels of genetic and transcriptomic analysis‚Äîspecifically at the **Gene, Exon, Junction, and Transcript (Isoform)** level‚Äîis highly important for distinguishing Major Depressive Disorder (MDD) from Bipolar Disorder (BP).

A simple gene-level analysis often masks crucial distinctions because both disorders share risk genes and common depressive symptoms. The finer-grained transcriptomic analysis allows researchers to pinpoint the exact molecular mechanisms that differentiate these conditions.

## üîç Why Resolution Matters: Transcriptomics Beyond the Gene

The key importance of examining differential gene expression at these finer levels (Exon, Junction, and Transcript) lies in the process of **Alternative Splicing**.

### 1. Differential Transcript (Isoform) Usage
A single gene can produce multiple protein versions (isoforms) through alternative splicing. These different isoforms can have opposing functions or be expressed in a cell type-specific manner, even if the overall gene expression level remains unchanged.

* **Importance:** MDD and BP might show differences not in *whether* a gene is expressed (gene level), but *which version* of the protein (transcript/isoform) is being produced. Identifying these specific isoforms can be a powerful, distinct molecular signature.

### 2. Exon and Junction Level Analysis (Splicing)
Differential Exon Usage (DEU) and Junction analysis directly investigate the machinery of alternative splicing.

* **Importance:** Alterations in **RNA processing and splicing** have been explicitly identified as one of the fundamental molecular processes associated with MDD risk and are increasingly studied in BP. Identifying a specific splice **junction** difference between MDD and BP could reveal a unique regulatory defect that causes one disorder but not the other. This detail is missed when only looking at total gene expression.

### 3. Identifying Unique Biological Pathways
High-resolution transcriptomics allows for the identification of **unique regulatory programs** and distinct biological pathways:

* Studies have revealed that while the disorders share some overlap, they are driven by different regulatory factors:
    * **BP** often shows predominant control by **immune-regulatory factors** and robust **immune system activation**.
    * **MDD** may show stronger alterations in **stress response** and **metabolic pathways**.
* This differential pathway dysregulation suggests distinct underlying mechanisms, which is the ultimate goal for developing precision medicine.

---

## üìö Supporting References and Findings

Current research is moving toward these higher-resolution approaches to solve the diagnostic challenge. Here are key themes and concepts from the literature:

* **Transcriptome-Wide Association Studies (TWAS) and RNA-seq:** Large-scale studies integrating genomic and transcriptomic data (RNA sequencing or RNA-seq) are being used to identify differential expression, not just at the gene level but across the entire transcriptome. These analyses specifically aim to identify biomarkers for **differential diagnosis** (Reference 2.3, 2.4).
* **Unique Regulatory Programs:** Large-scale transcriptomic analyses comparing MDD, BP, and Schizophrenia found that each disorder is regulated by a distinct set of **transcription factors**, confirming unique molecular signatures underlying the shared and distinct clinical presentations (Reference 1.4, 2.1).
* **Focus on Splicing:** Studies recognize that NGS (Next-Generation Sequencing) approaches like RNA-seq are more accurate and crucial because they can **detect alternative splicing** and measure differences in splicing events, which are known to be significant contributors to neuropsychiatric disorders (Reference 3.4).


## Methods used in this project

![Flowchart](https://github.com/karbalaei/MDD_BP/blob/main/graphs/Flowchart.jpg) 

In this proect , these analysis has been done yet :

- Find differentially expressed features( gene, transcripts, exon, junction) or **DEFs**. [Link](https://github.com/karbalaei/MDD_BP/tree/main/Diffierentially_expression_feature)
- Co-expressiopn networks analyzed using **WGCNA** package [link](https://github.com/karbalaei/MDD_BP/tree/main/wgcna)
- **Gene-set enrichmnt** of DEFs. [link](https://github.com/karbalaei/MDD_BP/tree/main/gene_set_enrichmnet)
- Functional Summary-data ImputatiOn Transcriptome-Wide Association Studies (**Fusion-TWAS**) which is primarily designed to use GWAS summary statistics combined with expression weights calculated from a separate reference panel of individuals with both genotype and expression data. [link](https://github.com/karbalaei/MDD_BP/tree/main/TWAS)
- **IsoTWAS** which goes beyond gene-level expression and focuses on isoform-specific expression (ISE). This is crucial because different isoforms of the same gene can have distinct functions and tissue-specific regulation. [link](https://github.com/karbalaei/MDD_BP/tree/main/isoTWAS)
- **Leafcutter** which is a computational tool designed to analyze splicing variation across samples and tissues, specifically focusing on intron usage. [link](https://github.com/karbalaei/MDD_BP/tree/main/leafcutter)

You can find more datails in their specific pages. 

## References
1. Panagiotaropoulou, G. et al. (2025) ‚ÄòIdentifying genetic differences between bipolar disorder and major depression through multiple genome-wide association analyses‚Äô, The British Journal of Psychiatry, 226(2), pp. 79‚Äì90. doi:10.1192/bjp.2024.125.
2. Yang, R., Zhao, Y., Tan, Z., Lai, J., Chen, J., Zhang, X., Sun, J., Chen, L., Lu, K., Cao, L. and Liu, X., 2023. Differentiation between bipolar disorder and major depressive disorder in adolescents: from clinical to biological biomarkers. Frontiers in human neuroscience, 17, p.1192544.
3. Tonozzi, T. R. et al. (2018) ‚ÄòPharmacogenetic Profile and Major Depressive and/or Bipolar Disorder Treatment: a Retrospective, Cross-Sectional Study‚Äô, Pharmacogenomics, 19(15), pp. 1169‚Äì1179. doi: 10.2217/pgs-2018-0088.
4. Wilcox, C., 2020. Can Genetics Help Us Distinguish Bipolar Disorder from Major Depression?. NEJM Journal Watch, p.NA51036.
5. Panagiotaropoulou, G., Hellberg, K.L.G., Coleman, J.R., Seok, D., Kalman, J., Mitchell, P.B., Schofield, P.R., Forstner, A.J., Bauer, M., Scott, L.J. and Pato, C.N., 2025. Identifying genetic differences between bipolar disorder and major depression through multiple genome-wide association analyses. The British Journal of Psychiatry, 226(2), pp.79-90.